Disclosures: Madeleine Chang: Nothing to Disclose, Mazen Noureddin: ltimmune, BI, Cytodyn, 89BIO, GSK, Madrigal, Merck, Novo Nor: Terns,Takeda, Zydus., Allergan, Akero, BI, BMS, Gilead, Galectin, Zydus GSK: Terns, Corcept, Takeda, Madrigal, Novartis, Novo Nordisk, Rivus Pharma, Cytodyn, and ChronWell: Stock privately held company 837 NONINVASIVE ASSESSMENT OF STEATOTIC LIVER DISEASE IN INDIVIDUALS WITH CLASS 2 AND CLASS 3 OBESITY Michael Thornton 1 Jang Hwan Cho 1 Idan Steinberg 1 Jing Gao 2 Colby Adamson 2 , 1 ENDRA Life Sciences Inc, 2 Rocky Vista University Background: The current standard of practice in the noninvasive assessment of steatotic liver disease at the point-of-care, is by quantitative Ultrasound (QUS)
The voxel dimensions were set to 34 mm (AP) 11 mm (RL) 16 mm (FH)
151 Triggering ferroptosis using system Xc inhibitors Erastin is a first-generation ferroptosis inducer that directly suppresses system Xc 1
UPS participates in both pro- and anti-fibrotic processes through the degradation of several TGF-/Smad signaling pathway constituents
